The Vascular and Cognitive Effects of Chronic High-flavanol Intake in Healthy Males
- Conditions
- Healthy
- Interventions
- Dietary Supplement: High-flavanol milk choocolateDietary Supplement: Low-flavanol milk chocolate
- Registration Number
- NCT02789761
- Lead Sponsor
- University of Reading
- Brief Summary
A randomised, placebo-controlled, parallel human dietary intervention trial conducted in 33 healthy males to investigate the vascular and cognitive effects of bi-daily consumption of high-flavanol (epicatechin-rich) milk chocolate over a 2-week intervention period. Subjects visited the Hugh Sinclair Unit of Human Nutrition on 3 separate occasions; at the beginning, end and post-intervention.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Male
- Target Recruitment
- 34
Not provided
- Haemoglobin (anaemia marker) < 125 g/l
- Gamma GT (liver enzymes) > 80 IU/l
- Total Cholesterol > 6.5 mmol/l
- Suffered a myocardial infarction or stroke in the last 12 months
- Suffers from any cardiovascular or metabolic disorders
- Suffers from any blood-clotting disorder, and/or takes supporting medication
- Any dietary restrictions or on a weight reducing diet
- On any lipid-modifying or blood pressure lowering medication
- Consuming any specific vitamin/ herbal supplements or fish oils
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description High-flavanol milk chocolate High-flavanol milk choocolate Bi-daily consumption of 12 g portion of a high-flavanol milk chocolate containing approximately 35 mg of (-)-epicatechin for 2-weeks (14 days) Low-flavanol milk chocolate Low-flavanol milk chocolate Bi-daily consumption of 12 g portion of a low-flavanol milk chocolate containing approximately \<1 mg of (-)-epicatechin for 2-weeks (14 days)
- Primary Outcome Measures
Name Time Method Flow-mediated Dilation (FMD) Change from baseline at 14 days Ultrasound-based assessment of brachial artery reactivity following induced reactive hyperemia
- Secondary Outcome Measures
Name Time Method Blood pressure (BP) Change from baseline at 14 days Acute assessment of systolic and diastolic BP (3 repeats)
Plasma Nitrite & Nitrate analysis Change from baseline at 14 days HPLC-based system with inbuilt colorimetric Griess reaction assay for the assessment of Nitrite \& Nitrate in plasma
Endothelial progenitor cells and Microparticles Change from baseline at 14 days Flow cytometric analysis using whole blood
Serum analysis of insulin Change from baseline at 14 days ELIZA kits for determination of insulin concentration in serum
Plasma flavanol metabolite analysis Change from baseline at 14 days HPLC-MS assessment of metabolite profile and content of plasma
Serum analysis of cardivascular-related blood marker(s) concentration Change from baseline at 14 days ILAB assessment of serum content of glucose, Triglycerides, total cholesterol, HDL-cholesterol, C-reactive protein and Non-esterified fatty acids
Executive Function Change from baseline at 14 days Assessed by cognitive test battery